胎儿生长受限对早产子痫前期期待治疗孕妇妊娠结局的影响
该研究为PIE和PI2试验的二次分析,纳入202例26至32周子痫前期期待治疗孕妇,其中92例(45.5%)合并胎儿生长受限(FGR)。FGR组妊娠潜伏期中位数为6.8天,对照组为15.3天,FGR组达到34周妊娠的比例更低、因疑似胎儿窘迫剖宫产率更高、婴儿死亡及机械通气率更高,母体并发症无显著差异。
要点
- 早产子痫前期期待治疗孕妇中FGR发生率达45.5%,合并FGR者妊娠潜伏期更短(中位6.8天 vs 15.3天)。
- FGR组达到34周妊娠的比例更低(12.0% vs 30.9%),因疑似胎儿窘迫剖宫产率更高(64.1% vs 36.4%)。
- FGR组婴儿死亡率(14.1% vs 4.5%)及需插管机械通气率(15.2% vs 5.5%)均更高,母体并发症无显著差异。
核心结论
- FGR在早产子痫前期期待治疗孕妇中常见,且与更短的妊娠潜伏期、更多急诊剖宫产、更少成功引产及更高的新生儿发病率和死亡率相关。
研究设计与样本
- PIE和PI2随机对照试验的二次分析,共纳入202例26至32周子痫前期期待治疗孕妇,仅纳入PI2试验的安慰剂数据,结局数据前瞻性收集至预产期后6周。
诊断标准与关键数值
- FGR采用Delphi共识定义;FGR组妊娠潜伏期中位数为6.8天,对照组为15.3天(校正后变化倍数0.49,95%CI 0.33-0.74,P<0.001)。
临床应用与阅片要点
- 对于早产子痫前期期待治疗的孕妇,合并FGR可能提示妊娠潜伏期更短、需更密切监测胎儿状况并预期更高的急诊剖宫产及新生儿不良结局风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess whether coexisting fetal growth restriction (FGR) influences pregnancy latency among women with preterm pre-eclampsia undergoing expectant management. Secondary outcomes assessed were indication for delivery, mode of delivery and rate of serious adverse maternal and perinatal outcomes.
METHODS: We conducted a secondary analysis of the Pre-eclampsia Intervention (PIE) and the Pre-eclampsia Intervention 2 (PI2) trial data. These randomized controlled trials evaluated whether esomeprazole and metformin could prolong gestation of women diagnosed with pre-eclampsia between 26 and 32 weeks of gestation undergoing expectant management. Delivery indications were deteriorating maternal or fetal status, or reaching 34 weeks' gestation. FGR (defined by Delphi consensus) at the time of pre-eclampsia diagnosis was examined as a predictor of outcome. Only placebo data from PI2 were included, as the trial showed that metformin use was associated with prolonged gestation. All outcome data were collected prospectively from diagnosis of pre-eclampsia to 6 weeks after the expected due date.
RESULTS: Of the 202 women included, 92 (45.5%) had FGR at the time of pre-eclampsia diagnosis. Median pregnancy latency was 6.8 days in the FGR group and 15.3 days in the control group (difference 8.5 days; adjusted 0.49-fold change (95% CI, 0.33-0.74); P < 0.001). FGR pregnancies were less likely to reach 34 weeks' gestation (12.0% vs 30.9%; adjusted relative risk (aRR), 0.44 (95% CI, 0.23-0.83)) and more likely to be delivered for suspected fetal compromise (64.1% vs 36.4%; aRR, 1.84 (95% CI, 1.36-2.47)). More women with FGR underwent a prelabor emergency Cesarean section (66.3% vs 43.6%; aRR, 1.56 (95% CI, 1.20-2.03)) and were less likely to have a successful induction of labor (4.3% vs 14.5%; aRR, 0.32 (95% CI, 0.10-1.00)), compared to those without FGR. The rate of maternal complications did not differ significantly between the two groups. FGR was associated with a higher rate of infant death (14.1% vs 4.5%; aRR, 3.26 (95% CI, 1.08-9.81)) and need for intubation and mechanical ventilation (15.2% vs 5.5%; aRR, 2.97 (95% CI, 1.11-7.90)).
CONCLUSION: FGR is commonly present in women with early preterm pre-eclampsia and outcome is poorer. FGR is associated with shorter pregnancy latency, more emergency Cesarean deliveries, fewer successful inductions and increased rates of neonatal morbidity and mortality. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Cluver, Bergman, Bergkvist, et al. Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2023. PMID: 37289938. doi:10.1002/uog.26282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。